Highlight
- Toripalimab is a PD-1 inhibitor approved for RM-NPC, now launched in India, the third country to access it after China and the U.S.
- It is indicated for use with chemotherapy or as monotherapy, showing a 48% reduction in progression or death risk.
- Dr. Reddy’s aims to enhance oncology care with Toripalimab, addressing unmet needs in India, a country with high NPC disease burden.
- The launch aligns with Dr. Reddy’s strategy to expand access to innovative cancer treatments in emerging markets.